About Abbott Biotech Ventures
Abbott Biotech Ventures is a venture capital firm founded in 2009. It is primarily based out of Lake Forest, United States. As of Jan 2012, Abbott Biotech Ventures has invested in 4 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across Life Sciences and High Tech sectors. Most recently it participated in the $***** Series B round of Exicure Overall, Abbott Biotech Ventures portfolio has seen 1 IPO and 2 acquisitions, namely Exicure and Alvine Pharma.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Seed & 1 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Abbott Biotech Ventures' List of All Investments
Abbott Biotech Ventures has a portfolio of 4 companies. Their most notable investments are in Creabilis and Exicure.Their portfolio spans across and United States. They have invested in Life Sciences, High Tech, across Series B, Seed and 1 more. Here is the list of all investments by Abbott Biotech Ventures:1. Exicure
Exicure (formerly AuraSense Therapeutics) develops a new class of immunomodulatory and gene silencing drugs against validated targets. It uses spherical nucleic acid (SNA) technology platform to build a pipeline of products for a range of diseases. The company's drug can be used for oncology (solid tumours), immunology (Psoriasis, Inflammatory disorders).
Key facts about Exicure
- Founded Year: 2009
- Location: Skokie (United States)
- Annual Revenue: $0 - $1M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $72.3M
- Employee Count: 4 as on Aug 31, 2026
- Investors: Abingworth, AbbVie and 18 Others
- Latest Funding Round: Post IPO, Nov 2024, $*****
- Highlight: Public
Online platform offering slot games with QRIS payment and exclusive bonuses. This platform is a destination for online gaming, specializing in slot games. It provides a seamless experience with QRIS payment integration, enabling instant deposits via mobile banking and e-wallets. The platform offers a variety of slot games, including popular titles and new releases, with features like scatter bonuses and VIP membership perks. It focuses on user experience, offering customer support through live chat and multiple channels. The platform promotes responsible gaming and provides a secure environment for players to enjoy their favorite slot games. It also features login and registration options, along with promotional offers and bonus programs.
Key facts about Alvine Pharma
- Founded Year: 2005
- Location: San Carlos (United States)
- Stage: Acquired
- Total Funding till date: $135M
- Investors: AbbVie, Sofinnova Investments and 7 Others
- Latest Funding Round: Series B, May 14, 2013, $*****
- Highlight: Acquired
Event ticketing platform connecting organizers and attendees for seamless experiences. This platform empowers organizers to create and sell tickets for their events, while providing attendees with a user-friendly experience to discover and book events. It offers features like event creation, ticket sales, upcoming event listings, and organizer profiles. The platform aims to streamline the event booking process, fostering connections between organizers and attendees. It provides a dashboard for professionals and subscribers, along with support resources like customer support, contacts, feedback, and a help sitemap. The platform also emphasizes staying up-to-date with favorite events through notifications. It is a SaaS based platform with login and subscription features.
Key facts about NeuroGenetic Pharmaceuticals
- Founded Year: 2009
- Location: Del Mar (United States)
- Stage: Seed
- Total Funding till date: $2.04M
- Employee Count: 3 as on May 31, 2026
- Investors: NIA, Abbott Biotech Ventures and 1 Other
- Latest Funding Round: Grant (prize money), Nov 10, 2015, $*****
- Highlight: Editors' Pick
4. Creabilis
Creabilis is a specialty pharmaceutical company that develops medicines for skin disorders. Pipeline includes clinical and pre-clinical drug candidates. The company's lead product CT327 a Phase III-ready topical treatment for chronic pruritus (itch). Creabilis is also developing other drug candidates, including CT340, a Phase I-ready drug that also targets chronic pruritus.
Key facts about Creabilis
- Founded Year: 2003
- Location: Westlake Village (United States)
- Stage: Acqui-Hired
- Total Funding till date: $50.9M
- Investors: Kreos Capital, NeoMed and 4 Others
- Latest Funding Round: Grant (prize money), Apr 23, 2013, $*****
Abbott Biotech Ventures' Investments by Stage
Abbott Biotech Ventures has made 2 investments in Series B stage with an average round size of $12.7M, 1 investment in Seed stage with an average round size of $500K and 1 investment in Series A stage.Stage of entry | No. of Investments |
|---|---|
Series B | 2 |
Seed | 1 |
Series A | 1 |
Note: We have considered here, only first round of investments
Abbott Biotech Ventures' Investments by Sector
Abbott Biotech Ventures has a diverse portfolio, with companies operating in the Life Sciences and High Tech. Notably, it has invested in 4 Tech companies, 3 Enterprise (B2B) companies and 1 Consumer (B2C) company.Sector | No. of Investments |
|---|---|
Life Sciences | 4 |
High Tech | 1 |
Note: We have considered here, only first round of investments
Abbott Biotech Ventures' Investments by Geography
Abbott Biotech Ventures has made most investments in United States (4).Abbott Biotech Ventures' recent investments
Abbott Biotech Ventures has not made any investment in 2026 so far.Here are the most recent investments by Abbott Biotech Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 05, 2012 | United States | Series B | 2543 | - | |
Dec 22, 2011 | United States | Seed | 8327 | - | |
Oct 04, 2011 | United States | Series B | 4991 | [+1] | |
May 26, 2010 | United States | Series A | 4355 | - |
IPOs and Publicly Listed companies in Abbott Biotech Ventures' Portfolio
1 of Abbott Biotech Ventures' portfolio company became public - Exicure. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in May 2018.Here are Abbott Biotech Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 22, 2018 | Jan 05, 2012 | Series B | 8582 |
Acquired companies in Abbott Biotech Ventures' Portfolio
2 companies from Abbott Biotech Ventures' portfolio have been acquired. The most recent acquisition was Creabilis in Dec 2016 by Sienna Biopharmaceuticals for $*****.Here are Abbott Biotech Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 06, 2016 | Oct 04, 2011 | Series B | 2952 | |
Mar 15, 2016 | May 26, 2010 | Series A | 7513 |
Co-investors of Abbott Biotech Ventures
Over the past 16 years, 27 investors have co-invested in Abbott Biotech Ventures's portfolio companies. This includes funds and angels.
- Invested before Abbott Biotech Ventures: InterWest Partners, Cargill Ventures and 6 others have invested in rounds before Abbott Biotech Ventures. There is 1 company where InterWest Partners has invested before Abbott Biotech Ventures and 1 company where Cargill Ventures has invested before Abbott Biotech Ventures.
- Invested after Abbott Biotech Ventures: A total of 19 investors have invested in Abbott Biotech Ventures's portfolio after their investments. Top Investors include AbbVie (2 companies), Cbiusa (1 company) and Abingworth (1 company).
Recent News related to Abbott Biotech Ventures
•
